New antibody drug shows promise in fighting advanced cancers

NCT ID NCT04452955

Ongoing Disease control Sponsor: Intra-IMMUSG Pte Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRL3-zumab
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 2 trial with only 51 participants, so results may not apply to all patients. The drug may not shrink tumors or improve survival, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89014, United States
HonorHealth Research

Scottsdale, Arizona, 85258, United States
Norton Healthcare

Louisville, Kentucky, 40200, United States
St. Jude Medical Center

Fullerton, California, 92835, United States
The Angeles Clinic

Los Angeles, California, 90025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.